
Aug 20, 2026 · 20 min
Target, Moderna and AI Face Three Very Different Growth Tests
Behind The Most Exciting Stock Pop In Years!
The episode connects a retailer’s uncertain recovery, a biotech breakthrough and worsening AI economics to the question of whether market enthusiasm can last.
- 1Target’s improving sales and digital strategy face tariff distortion and formidable competition from Walmart and Amazon.
- 2Moderna’s personalized mRNA cancer-vaccine results could broaden its business beyond vaccines and explain the stock’s dramatic surge.
- 3OpenAI’s slower growth and faster-rising losses sharpen questions about pricing, market share and a potential IPO race with Anthropic.
Don't miss
Moderna’s major personalized cancer-vaccine results produce a dramatic market reaction and reshape the company’s possible future in oncology.
The brief
Lou Whiteman and Travis Holy examine Target’s improved sales and same-store performance, while warning that a tariff refund inflated earnings and may make the turnaround look stronger than it is.
Target’s long-term case depends on more than a better quarter: the hosts weigh its pricing, dividend, digital operations and Shipt integration against Walmart and Amazon.
Moderna’s phase three personalized mRNA cancer-vaccine results trigger a dramatic stock surge, raising the possibility that the company could expand from vaccines into oncology.
The AI discussion turns to OpenAI’s 18% quarter-over-quarter growth, faster-rising operating losses and lower API prices, which may signal investment—or worsening economics.
OpenAI and Anthropic sit inside a wider investment cycle spanning hyperscalers, neoclouds and chip companies; future S-1 filings could clarify costs, obligations and IPO prospects.
What was said on this episode
22 statements · 11 positive · 8 negative · 1 mixed · 2 neutral
Target lowered prices on over 10,000 items to attract budget-conscious shoppers.
“they've lowered prices on more than 10,000 items to try to attract more budget-conscious shoppers.”
Listen at 0:59
Target is expanding into digital and service-based revenue channels.
“Target is really trying to expand more into the digital and service-based revenue channels.”
Listen at 1:06
Target’s stock rose nearly 60% year to date.
“target stocks almost up 60% year to date.”
Listen at 2:11
Sub-4% comparable-sales growth will not sustain Target’s stock indefinitely.
“under 4% comp sales gains won't sustain the stock forever.”
Listen at 2:40
Target’s price-cutting differentiation strategy is not sustainable.
“That doesn't sound like a sustainable strategy.”
Listen at 3:07
Target has not yet established a clear reason for customers to choose it.
“I still don't think we have the answer to that question for Target.”
Listen at 3:47
Target needs consistent growth above 4–5% for its dividend to matter to investors.
“you got to grow better than four or 5% consistently for that dividend to matter in terms of an investment decision for me.”
Listen at 5:15
Target’s digital business is moving in the right direction.
“But at least they're heading in the right direction.”
Listen at 5:44
Moderna’s personalized cancer-vaccine trial is a major milestone.
“This is a major milestone”
Listen at 8:05
Each personalized vaccine is coded to the patient’s specific tumor mutations.
“each vaccine is custom coded to a patient's specific tumor fingerprint”
Listen at 10:18
Manufacturing each personalized vaccine takes about one month after biopsy.
“it takes about a month to manufacture from the time of the biopsy.”
Listen at 10:22
Moderna is approaching a major transition beyond vaccines.
“Moderna is closing in on a huge, huge leap for them.”
Listen at 10:53
Moderna could transition from a vaccine company into an oncology company.
“They are going from being a vaccine company, with that vaccine kind of out of favor in the market right now, to potentially being an oncology company”
Listen at 10:58
Moderna’s personalized cancer vaccine may not receive approval for at least one year.
“They're looking at the next year at earliest before approval.”
Listen at 12:00
The personalized cancer vaccine’s cost and scalability remain uncertain.
“there are still huge questions about cost and feasibility at scale.”
Listen at 12:04
Moderna was a better purchase last September than at present.
“I think that would have been a great time to buy in. I'm less sure today”
Listen at 13:37
OpenAI is deeply unprofitable and becoming less profitable each quarter.
“OpenAI is deeply unprofitable. and growing more unprofitable by the quarter.”
Listen at 15:39
OpenAI is investing heavily to pursue future growth.
“They are investing for future growth.”
Listen at 16:05
OpenAI’s investments could succeed if they produce a later revenue surge.
“If they are doing these investments and there is a huge revenue burst later, then this all will have worked out fine.”
Listen at 16:42
The eventual winner between OpenAI and Anthropic remains unknown.
“The most honest answer is we don't know who the winner here is yet.”
Listen at 16:59
OpenAI and Anthropic can both continue growing within their respective niches.
“these are both companies within their respective niches that can continue to grow and thrive.”
Listen at 17:51
Anthropic’s revenue run rate could support a public valuation up to $2 trillion.
“their revenue run rate, which just surpassed $65 billion. could anchor a public valuation of up to $2 trillion”
Listen at 18:11
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.